- Factor V Leiden
- Prothrombin 20210
- Antiphospholipid Syndrome
Hypercoagulability Market was valued at USD 652 million in 2022 and is poised to grow at a CAGR of 6.4% over 2023-2029. Hypercoagulability, also known as thrombophilia, is an abnormality of blood coagulation that increases the risk of thrombosis, and the most common conditions associated with thrombophilia are deep vein thrombosis and pulmonary embolism, which are collectively known as venous thromboembolism. According to the Europe PMC, venous thromboembolism has an incidence ranging between 1 and 5 in 1000 per year in the general population. The rising cases of hypercoagulability risk factors such as cancers and heart diseases are driving the hypercoagulability market growth. whereas, the cost of treatment might hinder the market growth. The initiatives by governments and non-government organizations will act as an opportunity for the market to expand.
In May 2020, the US FDA approved Deciphera Pharmaceuticals’s Qinlock (Ripretinib) tablets for advanced gastrointestinal stromal tumors.
Fastest Growing Market
Due to various initiatives from pharmaceutical companies and government organizations, and the increasing risk factors of hypercoagulability, there will be a positive impact on market growth. For instance, in July 2022, the National Blood Clot Alliance established the Council for Emerging Researchers in Thrombosis to serve as a forum for researchers working in thrombosis and thrombophilia to promote and carry out research and scientific activities. However, accessibility to primary care for the patients could pose a hindrance to the market growth.
The Hypercoagulability market was valued at USD 652 million in 2022 and is expected to grow at a 6.4% CAGR over the forecast period 2023 – 2029.
The initiatives by governments and non-government organizations are the key opportunities for the Hypercoagulability market.
The rising cases of hypercoagulability risk factors such as cancers and heart diseases are the growth drivers in the Hypercoagulability market.
Yino Pharma Limited, Sanofi, Teva Pharmaceutical Industries Ltd., Shenzhen Hepalink Pharmaceutical, Techdow Pharmaceutical Co., Ltd., Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Novartis AG, Nanjing Jianyo, Biochemical Pharmaceutical Co., Ltd., Hikma Pharmaceuticals PLC, Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Fresenius Kabi AG, Eisai Co., Ltd., and Aspen Holdings are a few companies operating in the Hypercoagulability market.